^
    Back
    Association details:
    Biomarker:TUBB3 expression
    Cancer:Fallopian Tube Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Ixempra (ixabepilone) (Microtubule inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Cancer
    Title:

    Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

    Published date:
    02/11/2022
    Excerpt:
    Participants were randomised to receive ixabepilone 20 mg/m2 days 1, 8, 15 with (IXA + BEV) or without (IXA) bevacizumab...Both regimens were well-tolerated. TUBB3 expression did not predict response...TUBB3 is not a predictive biomarker.
    DOI:
    10.1038/s41416-022-01717-6
    Trial ID:
    NCT03093155
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SGO 2021
    Title:

    Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

    Published date:
    03/19/2021
    Excerpt:
    The goal of this multi-center randomized phase II study was to assess the activity and safety of ixabepilone with bevacizumab compared to ixabepilone alone in patients with platinum resistant/refractory ovarian, fallopian tube, or primary peritoneal cancer. TUBB3 expression did not predict response in either arm.